N. S. Boyko

N. S. Boyko

Auto-generated profile, based on publicly available information

N. S. Boyko

North-Western District Scientific and Clinical Center named after L.G. Sokolov of the Federal Medical and Biological Agency

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2023 in Pirogov Russian Journal of Surgery
Verified
Journal Article
Closed access
VKVictor Kashchenko
Victor Kashchenko
Alexei KamshilinAlexei Kamshilin
Alexei Kamshilin
VZValeriy Zaytsev
Valeriy Zaytsev
RPR.V. Pavlov
R.V. Pavlov
ABA.A. Bogatikov
A.A. Bogatikov
NBN.A. Boyko
N.A. Boyko
Objective. To evaluate the possibility of integrating tissue perfusion assessment techniques (ICG perfusion and imaging photoplethysmography — iPPG) into the system of intraoperative control points of laparoscopic interventions with a reconstructive component. Materials and methods. Quantitative assessment of ICG fluorescence and iPPG were used during 8 laparoscopically assisted interventions: gastrectomy for gastric cancer (total — 2 and distal — 1) and colorectal resections (left-sided colorectal resections — 4 and right hemicolectomy — 1). Results. Four stages are presented for the assessment of tissue perfusion: initial assessment, before intestine transection, before anastomosis formation, and evaluation of anastomosis. From the point of view of the significance of clinical decision-making, the «before intestine transection» stage is of great importance, due to the ease of transferring the resection level to the optimal tissue perfusion zone. Conclusion. Integration of tissue perfusion assessment techniques into the system of intraoperative checkpoints is possible and promising.

10 December 2022 in Head and Neck Tumors (HNT)
Verified
Journal Article
Open access
PDF file
PNP. A. Nikiforovich
P. A. Nikiforovich
APA. P. Polyakov
A. P. Polyakov
ISIlya Sleptsov
Ilya Sleptsov
NBN. S. Boyko
N. S. Boyko
YGYu. A. Gronskaya
Yu. A. Gronskaya
ЮГЮ. А. Гронская
Ю. А. Гронская
Introduction. Anaplastic thyroid cancer (ATC) is a very rare malignant tumor of the thyroid comprising 1–2 % of all thyroid cancers. In this pathology, response rate for standard systemic therapy is less than 15 %, and long-term results remain unsatisfactory. Additionally, there are no data conclusively showing that cytotoxic chemotherapy improves survival or quality of life in patients with ATC.Aim. To improve the results of treatment of patients with ATC through evaluation of the effectiveness of targeted therapy in cases of BRAFV600E mutation.Materials and methods. The multicenter prospective study included 29 patients with ATC IVB–C, T4a–bN1a–bM0–1. The patients were divided into 2 groups. The Group 1 (control) included 15 patients with resectable / nonresectable, metastatic / nonmetastatic ATC (without BRAFV600E mutation), stages IVB–C who received standard types of treatment (surgical intervention, radiation, and chemotherapy). The Group 2 consisted of 14 patients with nonresectable or metastatic ATC, stages IVB–C, who received combination therapy (surgical intervention, radiation, and chemotherapy) with inclusion of inhibitors of BRAF dabrafenib and trametinib in neoadjuvant and adjuvant regimens.Results. The study showed the effectiveness of targeted therapy with inhibitors of BRAF mutations in treatment of locally advanced non-operable metastatic ATC with BRAFV600E mutation. Overall response (complete response + partial response) in the Group 1 was 0 %, in the Group 2 it was 64 %. Therefore, treatment scheme dabrafenib + trametinib is a prmising approach to combination targeted therapy in patients with ATC and BRAFV600E mutation. Conclusion. Dabrafenib + trametinib is a promising combination targeted therapy option for patients with ATC with a BRAFV600 mutation demonstrates a high overall response rate, a prolonged duration of response, and an increase in survival rates with controlled toxicity.